IXICO Delivers Strong First Half Performance
Why we think this is very good
The trading update from IXICO plc indicates the company is performing well, with strong revenue growth of 26% year-over-year and an improvement in EBITDA. The company has a strong cash position and is debt-free, which provides financial flexibility. While the RNS does not provide details on the company's valuation, the overall performance metrics suggest the business is on a positive trajectory.
Key Points
- Revenues up 26% year-on-year to £3.2m
- Order book of £13.1m as at 31 March 2025
- Strong cash balance of £5.0m, debt-free
- Loss before interest, tax, depreciation, and amortisation expected to be £0.7m, an improvement from £1.3m loss in the prior year
Summary
IXICO plc, the medical imaging advanced analytics company, has delivered a strong trading performance in the first half of 2025. Key highlights include:
- Revenues up 26% to £3.2m compared to the prior year period
- Order book of £13.1m as at 31 March 2025, including new Alzheimer's Disease projects
- Strong cash balance of £5.0m and debt-free position
- Loss before interest, tax, depreciation, and amortisation expected to be £0.7m, an improvement from £1.3m loss in the prior year period
The company has made progress in expanding its operational services across the US market and further differentiating its imaging biomarker analysis pipelines for Alzheimer's and Parkinson's disease. IXICO expects the full impact of these initiatives to drive further contract wins in the second half of 2025 and into 2026.